Aspire BioPharma Competitors
| ASBP Stock | 0.80 -0.07 -8.05% |
Aspire BioPharma vs Integrated Wellness Correlation Details
Moderate diversification
Across the chosen horizon, Aspire BioPharma and Integrated Wellness show a correlation of 0.25 and fall into the Moderate diversification bucket. The overlap area shows the portion of risk that can be diversified away by holding both instruments together.
Moving together with Aspire Stock
Moving against Aspire Stock
Mean reversion analysis in Aspire BioPharma's involves identifying price extremes that diverge materially from the historical norm. High prices may deter value investors, while unusually low prices often attract buyers anticipating a recovery. Mean reversion in Aspire BioPharma is distinct from trend following, which rides momentum rather than betting on reversals.
Aspire BioPharma Competition Correlation Matrix
Reviewing how Aspire BioPharma moves relative to competing stocks can show whether peer exposure is reducing portfolio risk or simply repeating the same market bet. A reading near +1 usually means prices have moved in tandem, a reading near -1 suggests opposite movement, and a reading near zero points to weaker historical dependence.
| 0.0 | 0.0 | -0.46 | 0.0 | 0.0 | 0.15 | ANNA | ||
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | FIAC | ||
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | GAMC | ||
| -0.46 | 0.0 | 0.0 | 0.0 | 0.0 | -0.14 | CAUD | ||
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | LIVB | ||
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | INAQ | ||
| 0.15 | 0.0 | 0.0 | -0.14 | 0.0 | 0.0 | WEL | ||
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
Evaluating Aspire Stock requires separating price momentum from underlying operating strength versus competitors. Without risk-adjusted context, investors may overweight short-term returns and underweight the volatility required to achieve them. These indicators are quantitative in nature and help investors evaluate volatility and risk-adjusted expected returns across different positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ANNA | 8.21 | 1.94 | 0.28 | -0.44 | 7.15 | 27.72 | 109.32 | |||
| FIAC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| GAMC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| CAUD | 132.34 | 67.02 | 0.93 | 7.92 | 26.28 | 354.55 | 1,992 | |||
| LIVB | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| INAQ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| WEL | 0.25 | 0.00 | 0.03 | -0.04 | 0.66 | 0.25 | 6.66 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Aspire BioPharma financial statement analysis. It represents the amount of money remaining after all of Aspire BioPharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Compare Aspire BioPharma and related stocks such as AleAnna Class A, Focus Impact Acquisition, and Golden Arrow Merger Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANNA | -3.3 M | -3.3 M | -3.3 M | -3.3 M | -3.3 M | -3.3 M | -3.3 M | -3.3 M | -3.3 M | -3.3 M | -3.3 M | -3.3 M | -3.3 M | -5.2 M | -12.3 M | -11.1 M | -10.6 M |
| CAUD | -3.9 M | -3.9 M | -3.9 M | -3.9 M | -3.9 M | -3.9 M | -3.9 M | -3.9 M | -3.9 M | -3.9 M | -3.9 M | -4.5 M | -5.6 M | -4.6 M | -4.6 M | -4.1 M | -4.3 M |
Aspire BioPharma Competitive Analysis
Sizing up Aspire BioPharma against AleAnna, Focus Impact, and Golden Arrow reveals meaningful differences in scale and efficiency. At a 4.4 M valuation, Aspire BioPharma is a significant player in the space. AleAnna holds the larger valuation at 221.8 M versus 4.4 M. Market capitalization diverges sharply here: 66.3 M versus 4.4 M, giving Focus Impact a clear size advantage. Golden Arrow holds the larger valuation at 69.9 M versus 4.4 M.| Better Than Average | Worse Than Peers | View Performance Chart |
Aspire BioPharma Competition Peer Performance Charts
How to Analyze Aspire BioPharma Against Peers
Aspire BioPharma's peer analysis compares Aspire BioPharma with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Aspire BioPharma trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Aspire BioPharma leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Aspire BioPharma's beta is lower than the peer group average, meaning its stock tends to swing less during broad market moves. Competition analysis is most useful when price, margins, leverage, and growth are read together. For peer comparison, Aspire BioPharma has a market cap of 4.37 M.
Unless otherwise specified, data for Aspire BioPharma is compiled from periodic company reporting and market reference feeds and standardized for comparability. Updates may occur throughout the day.